Melanoma – Open Studies

Study Details:

Phase:

Sub Therapeutic Area :

Site:

s_external_protocol_id	Study Details	Phase	Sub Therapeutic Area	Sponsor	Site	PI	Study Coordinator	Team	Inclusion and Exclusion Criteria	Notes	s_treatment_stages	Therapeutic Area	s_recruitment_criteria	Open To Accrual	Open to Accrual Date (String)	Completely Closed Date (String)	Site Initiation Visit Date (String)	s_nick	s_other_id	Total Recruitment	Site Target	Percentage
17/209 PMCC Sponsored - 17/021 - CELEBRATE - NC229	CELEBRATE A Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF?mutant metastatic melanoma (The CELEBRATE study) 17/021	Phase I		Peter MacCallum Cancer Centre	PCCTU	Grant McArthur	PCCTU MoncC Team	PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT04720768?term=NCT04720768&draw=2&rank=1	RAF kinase, MEK 1/2 and CDK 4/6 inhibitors. VCA grant study, PMCC sponsored. Previous immunotherapy allowed. Investigator meeting will be set up to discuss recruitment and making study more accessible for patients. BRAF naive, or pre-treated - cannot put anyone one who has progressed on BRAF inihibitor.		Melanoma	A Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF?mutant metastatic melanoma (The CELEBRATE study)	Yes	23/12/2019		28/11/2019	CELEBRATE	17/021	11	10	1
19/203 - Replimune - RPL-002-18 - CERPASS - CT1169	CERPASS A Randomized, Controlled, Open-label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma. RPL-002-18	Phase II	Cutaneous SCC	Novotech	PCCTU	Annette Lim		PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT04050436?term=RPL-002-18&draw=2&rank=1	Anti-PD-1 monoclonal antibody + oncolytic virus. For pts with injectable disease.		Melanoma	A Randomized, Controlled, Open-label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma.	Yes	14/10/2019		28/11/2019	CERPASS	RPL-002-18	2	5	1
19/212 MIA - CT2019/258 - ABC-X - NC221	ABC-X A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain metastases. CT2019/258	Phase II		Melanoma Institute Australia	PCCTU	Grant McArthur	PCCTU MoncC Team	PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT03340129?term=ABC-X&draw=2&rank=1#eligibility	Lead site MIA Sydney. Overlap with ARRAY-818-201 for BRAF mutant pts. Eligibility criteria can be restrictive. Each lesion in pts needs to be treated by SRS. Difficult to recruit to.	1st Line	Melanoma	A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain metastases.	Yes	13/02/2020		13/02/2020	ABC-X	CT2019/258	10	20	1
19/87 Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126	cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788	Phase III	Cutaneous SCC	ICON Clinical Research	PCCTU	Danny Rischin		PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=R2810-ONC-1788&draw=2&rank=1#eligibility	Anti-PD-1 monoclonal antibody. Amendment underway to broaden the inclusion criteria. Recruitment slow.	Adjuvant	Melanoma	A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.	Yes	1/08/2019		3/09/2019	cPOST	R2810-ONC-1788	19	20	1
19/87 Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126	cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788	Phase III	Cutaneous SCC	ICON Clinical Research	PCCTU	Danny Rischin		PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=R2810-ONC-1788&draw=2&rank=1#eligibility	Anti-PD-1 monoclonal antibody. Amendment underway to broaden the inclusion criteria. Recruitment slow.	Neo-adjuvant	Melanoma	A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.	Yes	1/08/2019		3/09/2019	cPOST	R2810-ONC-1788	19	20	1
20/044 - IMPARP-HRD - VC007	IMPARP-HRD An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects 20/044, VC007	Phase II	Solid Tumour	Peter MacCallum Cancer Centre	PCCTU	Stephen Luen	EDD PMC	PCCTU EDD	https://clinicaltrials.gov/ct2/show/NCT04985721?term=NCT04985721&draw=2&rank=1			Melanoma	An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects	Yes	20/01/2022		20/01/2022	IMPARP-HRD	20/044, VC007	16	10	1
20/044 - IMPARP-HRD - VC007	IMPARP-HRD An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects 20/044, VC007	Phase II	Solid Tumour	Peter MacCallum Cancer Centre	Western Health	Keri-Lee Geneser			https://clinicaltrials.gov/ct2/show/NCT04985721?term=NCT04985721&draw=2&rank=1			Melanoma	An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects	Yes	29/05/2023		29/05/2023	IMPARP-HRD	20/044, VC007	0	15	1
20/17 MASC - GOTHAM - NC247	GOTHAM A phase Ib/II study of combination avelumab with peptide receptor radionuclide therapy or conventional fractionated radiotherapy in patients with metastatic Merkel cell carcinoma 10.17	Phase Ib/II	Merkel Cell Carcinoma	Melanoma and skin Cancer (MASC) trials	PCCTU	Lavinia Spain	PCCTU MoncC Team	PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT04261855?term=GOTHAM&draw=2&rank=1#eligibility	For treatment na�ve patients. Referral's welcome.		Melanoma	A phase Ib/II study of combination avelumab with peptide receptor radionuclide therapy or conventional fractionated radiotherapy in patients with metastatic Merkel cell carcinoma	Yes	7/10/2020		9/09/2020	GOTHAM	10.17	4	16	1
20/193 MASC - I-MAT0318 - NC252	A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma I-MAT0318	Phase II	Merkel Cell Carcinoma	Melanoma Institute Australia	PCCTU	Shahneen Sandhu	PCCTU MoncC Team	PCCTU MoncC		Early stage Merkel. Avelumab vs. Placebo. All local treatment is SoC, then randomised for 6 months.		Melanoma	A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma	Yes	7/09/2020		29/10/2020		I-MAT0318	10	15	1
20/212 Genentech - GO42273 - BELVA - CT1303	BELVA A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF BELVARAFENIB AS A SINGLE AGENT AND IN COMBINATION WITH EITHER COBIMETINIB OR COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH NRAS-MUTANT ADVANCED MELANOMA WHO HAVE RECEIVED ANTI?PD-1/PD-L1 THERAPY GO42273	Phase Ib		PPD	PCCTU	Shahneen Sandhu	PCCTU MoncC Team	PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT04835805?term=GO42273&draw=2&rank=1#eligibility		2nd Line	Melanoma	A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF BELVARAFENIB AS A SINGLE AGENT AND IN COMBINATION WITH EITHER COBIMETINIB OR COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH NRAS-MUTANT ADVANCED MELANOMA WHO HAVE RECEIVED ANTI?PD-1/PD-L1 THERAPY	Yes	13/04/2021	1/05/2024	25/03/2021	BELVA	GO42273	3	6	1
21/235 Melanoma institute - CA209-6FR/M21NDN - PCCTU - NC283	NADINA Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINA CA209-6FR/M21NDN	Phase III		Melanoma Institute Australia	PCCTU	Shahneen Sandhu	PCCTU MoncC Team	PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT04949113?term=CA209-6FR&draw=2&rank=1#eligibility	Two cycles of Ipilimumab-Nivolumanb followed by adjuvant Nivo.	Neo-adjuvant	Melanoma	Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINA	Yes	2/12/2021		2/12/2021	NADINA	CA209-6FR/M21NDN	27	22	1
21/253 - AstraZeneca - D553AC00001 - MONETTE - CT1458	MONETTE A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition D553AC00001	Phase II		Parexel International	PCCTU	Shahneen Sandhu		PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT05061134?term=MONETTE&draw=2&rank=1#eligibility		1st Line	Melanoma	A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition	Yes	23/11/2022		3/11/2022	MONETTE	D553AC00001	3	8	1
21/46 Erasca - ERAS-601-01 - FLAGSHP-1 - CT1358 (Monc B)	FLAGSHP-1 An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors (FLAGSHP-1) ERAS-601-01	Phase Ib	Solid Tumour	IQVIA	PCCTU	Danny Rischin		PCCTU MoncB	https://classic.clinicaltrials.gov/ct2/show/NCT04670679?term=ERAS-601-01&draw=2&rank=1			Melanoma	An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors (FLAGSHP-1)	Yes	28/06/2021		15/07/2021	FLAGSHP-1	ERAS-601-01	1	8	1
22/205 - AstraZeneca - D9350C00001 - AZD9592 - EGRET - CT1560	AZD9592 EGRET A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors D9350C00001	Phase I	Solid Tumour	AstraZeneca	PCCTU	Ben Solomon		PCCTU EDD	https://classic.clinicaltrials.gov/ct2/show/NCT05647122?term=D9350C00001&draw=2&rank=1#eligibility			Melanoma	A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors	Yes	19/01/2023		12/01/2023	AZD9592 EGRET	D9350C00001	2	8	1
22/25 - IO Biotech - IO102-IO103-013 (IOB-013) / MK3475-D18 (KN-D18) - CT1481	MK3475-D18 (KN-D18) An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma IO102-IO103-013	Phase III		Syneos	PCCTU	Shahneen Sandhu		PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT05155254?term=NCT05155254&draw=2&rank=1		1st Line	Melanoma	An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma	Yes	29/07/2022		28/07/2022	MK3475-D18 (KN-D18)	IO102-IO103-013	2	12	1
22/34 Antengene - ATG-101-001 (PROBE) - CT1471	PROBE A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas ATG-101-001	Phase I	Solid Tumour		PCCTU	Annette Lim		PCCTU EDD	https://clinicaltrials.gov/ct2/show/NCT04986865?term=NCT04986865&draw=2&rank=1			Melanoma	A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas	Yes	3/03/2022		30/03/2022	PROBE	ATG-101-001	1	10	1
22/57 - Harmony - R3767-ONC-2011 - CT1576	Harmony A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma R3767-ONC-2011	Phase III		ICON plc	Barwon	Anna Lomax		Medical Oncology	https://classic.clinicaltrials.gov/ct2/show/NCT05352672?term=R3767-ONC-2011&draw=2&rank=1#eligibility		1st Line	Melanoma	A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma	Yes	27/02/2023		20/02/2023	Harmony	R3767-ONC-2011	4	3	1
22/62 - Bristol Myers Squibb (BMS) - CA027-002 - CT1498	CA027002 A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers CA027-002	Phase I/II		Bristol Myers Squibb - BMS	PCCTU	Belinda Lee		PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT03400332?term=CA027-002&draw=2&rank=1#eligibility		2nd Line	Melanoma	A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers	Yes	28/04/2022		28/04/2022	CA027002	CA027-002	2	5	1
22/70 - Novartis - CDYP688A12101 - Novartis MUM - CT1501	Novartis MUM A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas CDYP688A12101	Phase I/II	Uveal	Novartis	PCCTU	Damien Kee		PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT05415072?term=CDYP688A12101&draw=2&rank=1#eligibility			Melanoma	A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas	Yes	31/08/2022		31/08/2022	Novartis MUM	CDYP688A12101	4	12	1
22/76 - MASTER Registry - NC317	MASTER Registry REAL WORLD MANAGEMENT AND OUTCOMES OF MELANOMA PATIENTS IN AUSTRALASIA USING THE MASTER REGISTRY. MASTER	TBC	Registry	Walter & Eliza Hall Institute of Medical Research - WEHI	Barwon	Anna Lomax		Registry			Adjuvant	Melanoma	REAL WORLD MANAGEMENT AND OUTCOMES OF MELANOMA PATIENTS IN AUSTRALASIA USING THE MASTER REGISTRY.	Yes	22/11/2022		22/11/2022	MASTER Registry	MASTER	43	30	1
22/95 - Pfizer - C4221026 (Flotilla) - CT1513	Flotilla AN OPEN-LABEL STUDY FOR CONTINUED TREATMENT ACCESS FOR PARTICIPANTS FROM THE C4221003 (ARRAY-818-103), C4221006 (ARRAY-818-201) AND THE C4221013 (ARRAY CLGX818X2109) ENCORAFENIB AND BINIMETINIB STUDIES C4221026	N/A	Other	Pfizer	PCCTU	George Au-Yeung		PCCTU LAT (Managed)	https://classic.clinicaltrials.gov/ct2/show/NCT05203172?term=C4221026&draw=2&rank=1#eligibility			Melanoma	AN OPEN-LABEL STUDY FOR CONTINUED TREATMENT ACCESS FOR PARTICIPANTS FROM THE C4221003 (ARRAY-818-103), C4221006 (ARRAY-818-201) AND THE C4221013 (ARRAY CLGX818X2109) ENCORAFENIB AND BINIMETINIB STUDIES	Yes	28/11/2022		21/11/2022	Flotilla	C4221026	1	1	1
23/117 - MSD - V940001 - 001-00 V940 - CT1659	001-00 V940 A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator- Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma V940001	Phase III		Merck Sharp & Dohme (MSD)	PCCTU	Shahneen Sandhu	PCCTU MoncC Team	PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT05933577?term=V940&draw=2&rank=1			Melanoma	A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator- Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma	Yes			10/08/2023	001-00 V940	V940001	0	15	1
23/23 - MSD - MK-7684A-010 - KEYVIBE-010 - CT1617	KEYVIBE-010 A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010) MK-7684A-010	Phase III		Merck Sharp & Dohme (MSD)	PCCTU	Shahneen Sandhu		PCCTU MoncC	https://classic.clinicaltrials.gov/ct2/show/NCT05665595?term=MK-7684A-010&draw=2&rank=1#eligibility			Melanoma	A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)	Yes	12/04/2023		15/03/2023	KEYVIBE-010	MK-7684A-010	4	25	1
23/55 - Harmony Adjuvant - R3767-ONC-2055 - CT1662	R3767-ONC-2055 A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma R3767-ONC-2055	Phase III		ICON plc	Barwon	Anna Lomax		Haematology	https://clinicaltrials.gov/ct2/show/NCT05608291?term=R3767ONC2055&draw=2&rank=1			Melanoma	A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma	Yes	15/09/2023		5/09/2023	R3767-ONC-2055	R3767-ONC-2055	0	2	1
ACRF - ACEMID - No CTA Finance - NC322	Australian Centre of Excellence in Melanoma Imaging & Diagnosis Cohort Study ACEMID	N/A			Bendigo	Robert Blum		BCC				Melanoma	Australian Centre of Excellence in Melanoma Imaging & Diagnosis Cohort Study	Yes	17/11/2022		17/11/2022		ACEMID	262		1
BMS - CA027-002 - CT1498	CA027002 A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers CA027-002	Phase I/II		Bristol Myers Squibb - BMS	Alfred - Medical Oncology	Andrew Haydon		ACT 2	https://classic.clinicaltrials.gov/ct2/show/NCT03400332?term=CA027-002&draw=2&rank=1#eligibility		2nd Line	Melanoma	A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers	Yes	22/07/2022		14/07/2022	CA027002	CA027-002	6	8	1
BMS - CA027-002 - CT1498	CA027002 A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers CA027-002	Phase I/IIa		Bristol Myers Squibb	Grampians Health	Prashanth Prithviraj			https://classic.clinicaltrials.gov/ct2/show/NCT03400332?term=CA027-002&draw=2&rank=1#eligibility		2nd Line	Melanoma	A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers	Yes			16/05/2022	CA027002	CA027-002	0	3	1
BMS - CA209-7CK - CT1154	A prospective observational study in patients receiving adjuvant nivolumab therapy for resected melanoma in Australia CA209-7CK	N/A		Bristol Myers Squibb - BMS	Epworth	Phillip Parente		Medical Oncology	https://classic.clinicaltrials.gov/ct2/show/NCT04146324?term=CA209-7CK&draw=2&rank=1#eligibility			Melanoma	A prospective observational study in patients receiving adjuvant nivolumab therapy for resected melanoma in Australia	Yes	9/04/2021		9/04/2021		CA209-7CK	0	10	1
BMS - CA2096GE - CheckMate-6GE - CT1473	CheckMate-6GE A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Administered Subcutaneously (Nivo SC) Versus Intravenous Administration of Nivolumab in Participants with Stage IIIA/B/C/D or Stage IV Adjuvant Melanoma Following Complete Resection CA2096GE	Phase III		BMS	Bendigo	Sam Harris			https://classic.clinicaltrials.gov/ct2/show/NCT05297565?term=CheckMate-6GE&draw=2&rank=1#eligibility	Adjuvant subcutaneous Nivo vs. IV study. Delivered at home.	1st Line	Melanoma	A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Administered Subcutaneously (Nivo SC) Versus Intravenous Administration of Nivolumab in Participants with Stage IIIA/B/C/D or Stage IV Adjuvant Melanoma Following Complete Resection	Yes			10/10/2022	CheckMate-6GE	CA2096GE	0	4	1
BMS - CA224-127 - CT1590	RELATIVITY-127 A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma CA224-127	Phase III		BMS	Bendigo	Sam Harris			https://classic.clinicaltrials.gov/ct2/show/NCT05625399?term=CA224-127&draw=2&rank=1#eligibility			Melanoma	A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma	Yes	31/03/2023		27/03/2023	RELATIVITY-127	CA224-127	1	5	1
BMS - CA224-127 - RELATIVITY-127 - CT1590	RELATIVITY-127 A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma CA224-127	Phase III		BMS	Alfred - Medical Oncology	Andrew Haydon			https://classic.clinicaltrials.gov/ct2/show/NCT05625399?term=CA224-127&draw=2&rank=1#eligibility			Melanoma	A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma	Yes	4/05/2023		27/04/2023	RELATIVITY-127	CA224-127	1	5	1
BMS - CA224-127 - RELATIVITY-127 - CT1590	RELATIVITY-127 A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma CA224-127	Phase III		BMS	LRH	Quan Tran			https://classic.clinicaltrials.gov/ct2/show/NCT05625399?term=CA224-127&draw=2&rank=1#eligibility			Melanoma	A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma	Yes	18/04/2023		26/04/2023	RELATIVITY-127	CA224-127	1	6	1
BMS - CA224098 - CT1462	RELATIVITY-098 A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma CA224098	Phase III		Bristol Myers Squibb	Grampians Health	Prashanth Prithviraj			https://clinicaltrials.gov/ct2/show/NCT05002569?term=NCT05002569&draw=2&rank=1		Adjuvant	Melanoma	A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma	Yes			28/02/2022	RELATIVITY-098	CA224098	0	5	1
Beigene - BGB-900-105 (AdvanTIG-105) - CT1468	Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors BGB-900-105	Phase Ib	Solid Tumour		Bendigo	Sam Harris			https://classic.clinicaltrials.gov/ct2/show/NCT04047862?term=NCT04047862&draw=2&rank=1			Melanoma	Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors	Yes	7/03/2022		28/02/2022		BGB-900-105	2	2	1
CCTG - ME.13 - STOP-GAP - NC218	STOP-GAP A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma. ME.13	Phase III			Alfred - Medical Oncology	Andrew Haydon		ACT 2	https://classic.clinicaltrials.gov/ct2/show/NCT02821013?term=NCT02821013&draw=2&rank=1	PD-1 inhibitor. Lead site St Vincent's Sydney. ANZMTG study. Pembro and nivo ok, patients need to be on active treatment prior to randomisation. For pts who have reached maximum tumour response on immunotherapy. Standard of care study, with duration as intervention. Open and recruiting. Trialling teletrial method across various hospitals.	1st Line	Melanoma	A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma.	Yes	12/11/2019		11/11/2019	STOP-GAP	ME.13	14	5	1
Covance - ATG-101-001 - PROBE - CT1471	PROBE A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas ATG-101-001	Phase I	Solid Tumour	Antengene (AUS) PTY. LTD	Alfred - Medical Oncology	Mark Voskoboynik		ACT 1	https://clinicaltrials.gov/ct2/show/NCT04986865?term=NCT04986865&draw=2&rank=1			Melanoma	A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas	Yes	30/03/2022		23/03/2022	PROBE	ATG-101-001	4	8	1
Evaxion Biotech Australia - EVX-01-001 - CT1589	EVX-01 An open label, single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in checkpoint inhibitor treatment na�ve adults with unresectable or metastatic melanoma EVX-01-001	Phase II		Evaxion Biotech Australia	Grampians Health	Sharad Sharma			https://classic.clinicaltrials.gov/ct2/show/NCT05309421?term=EVX-01-001&draw=2&rank=1#eligibility			Melanoma	An open label, single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in checkpoint inhibitor treatment na�ve adults with unresectable or metastatic melanoma	Yes			18/11/2022	EVX-01	EVX-01-001	0	1	1
George Clinical - CIBI334A101 - INNOVENT - CT1644	INNOVENT A Phase 1 Study of IBI334 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors CIBI334A101	Phase I	Solid Tumour	The George Institute	Grampians Health	Lizzie Lim			https://classic.clinicaltrials.gov/ct2/show/NCT05774873?term=CIBI334A101&draw=2&rank=1			Melanoma	A Phase 1 Study of IBI334 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors	Yes			5/07/2023	INNOVENT	CIBI334A101	0	12	1
Gilead - GS-US-548-5916 - ELEVATE HNSCC - CT1537	ELEVATE HNSCC GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma GS-US-548-5916	Phase II	Cutaneous SCC	Gilead	Alfred - Medical Oncology	Miles Andrews		ACT 3	https://classic.clinicaltrials.gov/ct2/show/NCT04854499?term=GS-US-548-5916&draw=2&rank=1#eligibility		1st Line	Melanoma	GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma	Yes	21/09/2022		13/10/2022	ELEVATE HNSCC	GS-US-548-5916	1	3	1
Gilead - GS-US-548-5916 - ELEVATE HNSCC - CT1537	ELEVATE HNSCC GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma GS-US-548-5916	Phase II	Cutaneous SCC	Gilead	Alfred - Medical Oncology	Miles Andrews		ACT 3	https://classic.clinicaltrials.gov/ct2/show/NCT04854499?term=GS-US-548-5916&draw=2&rank=1#eligibility		Adjuvant	Melanoma	GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma	Yes	21/09/2022		13/10/2022	ELEVATE HNSCC	GS-US-548-5916	1	3	1
Gilead - GS-US-548-5916 - ELEVATE HNSCC - CT1537	ELEVATE HNSCC GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma GS-US-548-5916	Phase II	Cutaneous SCC	Gilead	Alfred - Medical Oncology	Miles Andrews		ACT 3	https://classic.clinicaltrials.gov/ct2/show/NCT04854499?term=GS-US-548-5916&draw=2&rank=1#eligibility		Neo-adjuvant	Melanoma	GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma	Yes	21/09/2022		13/10/2022	ELEVATE HNSCC	GS-US-548-5916	1	3	1
IQVIA - LM302-01-201 - LANOVA - CT1476	LANOVA A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors LM302-01-201	Phase I/II	Solid Tumour	IQVIA	Alfred - Medical Oncology	Ben Markman		ACT 1	https://classic.clinicaltrials.gov/ct2/show/NCT05188664?term=NCT05188664&draw=2&rank=1			Melanoma	A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors	Yes	22/04/2022		21/04/2022	LANOVA	LM302-01-201	7	3	1
InxMed - IN10018-004 - CT1210	IN10018 A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects with Metastatic Melanoma IN10018-004	Phase Ib		InxMed	Alfred - Medical Oncology	Mark Shackleton	Anne Everts	ACT 1	https://classic.clinicaltrials.gov/ct2/show/NCT04109456?term=IN10018-004&draw=2&rank=1#eligibility	FAK inhibitor. Alfred single site submission. Good for pts with NRAF mutation. Can have previous lines of therapy. Initially opened as single agent study, will re-open with combination therapy. Open for RAS mutants. Study no longer open to Uveal melanoma.	2nd Line	Melanoma	A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects with Metastatic Melanoma	Yes	27/03/2020		27/03/2020	IN10018	IN10018-004	10	5	1
MASC - I-MAT0318 - NC252	A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma I-MAT0318	Phase II	Merkel Cell Carcinoma	Melanoma And Skin Cancer	Alfred - Medical Oncology	Mark Shackleton	Shelley Firth	ACT 2		Early stage Merkel. Avelumab vs. Placebo. All local treatment is SoC, then randomised for 6 months.		Melanoma	A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma	Yes	8/10/2020		8/10/2020		I-MAT0318	3	5	1
MASC Trials - SOCRATES-1 - SOCRATES - NC314	SOCRATES The Statins and progression of Coronary atherosclerosis in melanoma patients Treated with checkpoint inhibitors. SOCRATES-1	Phase II	Other	Monash University	Cabrini	Gary Richardson			https://classic.clinicaltrials.gov/ct2/show/NCT05180942?term=SOCRATES&cond=Melanoma&draw=2&rank=1#eligibility			Melanoma	The Statins and progression of Coronary atherosclerosis in melanoma patients Treated with checkpoint inhibitors.	Yes	14/12/2022		15/12/2022	SOCRATES	SOCRATES-1	0	20	1
MIA - CT2019/258 - ABC-X - NC221	ABC-X A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain metastases. CT2019/258	Phase II		Melanoma Institute Australia	Alfred - Medical Oncology	Andrew Haydon	Janet Andrew	ACT 2	https://classic.clinicaltrials.gov/ct2/show/NCT03340129?term=ABC-X&draw=2&rank=1#eligibility	Lead site MIA Sydney. Overlap with ARRAY-818-201 for BRAF mutant pts. Eligibility criteria can be restrictive. Each lesion in pts needs to be treated by SRS. Difficult to Recruit to.	1st Line	Melanoma	A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain metastases.	Yes	19/11/2020		19/11/2020	ABC-X	CT2019/258	4	6	1
MSD - MK-3475-630 - KEYNOTE-630 - CT1137	KEYNOTE-630 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630) MK-3475-630	Phase III	Cutaneous SCC	Merck Serono	Alfred - Medical Oncology	Mitchell Chipman	Jane Berry	ACT 2	https://classic.clinicaltrials.gov/ct2/show/NCT03833167?term=MK-3475-630&draw=2&rank=1#eligibility	Anti-PD-1 immunotherapy Adjuvant therapy for locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy	Adjuvant	Melanoma	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)	Yes	23/08/2019		7/08/2019	KEYNOTE-630	MK-3475-630	10	5	1
MSD - V940-001 - CT1659	V940 A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma V940-001	Phase III		Merck Sharp & Dohme (MSD)	Alfred - Medical Oncology	Andrew Haydon			https://classic.clinicaltrials.gov/ct2/show/NCT05933577?term=V940-001&draw=2&rank=1#eligibility			Melanoma	A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma	Yes			27/07/2023	V940	V940-001	0	15	1
Melanoma institute - CA209-6FR/M21NDN - NADINA - NC283	NADINA Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINA CA209-6FR/M21NDN	Phase III		Melanoma Institute Australia	Alfred - Medical Oncology	Miles Andrews		ACT 2	https://classic.clinicaltrials.gov/ct2/show/NCT04949113?term=CA209-6FR%2FM21NDN&draw=2&rank=1#eligibility	Two cycles of Ipilimumab-Nivolumanb followed by adjuvant Nivo.	Neo-adjuvant	Melanoma	Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINA	Yes	1/12/2021		3/03/2022	NADINA	CA209-6FR/M21NDN	12	10	1
Monash University - 02.19 IMAGE - NC253	IMAGE Melanoma surveillance photography (MSP) to improve early detection of melanoma in ultra-high and high risk patients 02.19	TBC		Monash University	Bendigo				https://classic.clinicaltrials.gov/ct2/show/NCT04385732?term=02.19&draw=2&rank=1#eligibility			Melanoma	Melanoma surveillance photography (MSP) to improve early detection of melanoma in ultra-high and high risk patients	Yes	24/01/2022		28/06/2021	IMAGE	2.19	25	50	1
Monash University - RELAY	TRialHub tELetriAge pilot studY RELAY	N/A		Monash University	Bendigo	Robert Blum						Melanoma	TRialHub tELetriAge pilot studY	Yes	8/02/2023		8/02/2023		RELAY	25	100	1
Novotech - HBI-8000-303 - CT1341	A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI 8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors	Phase III		Novotech	GVH	Myron Klevansky					2nd Line	Melanoma	A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI 8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors	Yes	3/05/2021		30/04/2021			3	1	1
Novotech - MHB036C-CP001EN - CT1561	MHB036C Phase 1/2, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants with Advanced or Metastatic Solid Tumors MHB036C-CP001EN	Phase I/II	Solid Tumour	Novotech	Cabrini	Gary Richardson			https://classic.clinicaltrials.gov/ct2/show/NCT05642949?term=MHB036C-CP001EN&draw=2&rank=1#eligibility			Melanoma	Phase 1/2, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants with Advanced or Metastatic Solid Tumors	Yes			9/03/2023	MHB036C	MHB036C-CP001EN	0	5	1
Novotech - MHB088C-CP001EN - CT1570	MHB088C Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants with Advanced or Metastatic Solid Tumors MHB088C-CP001EN	Phase I/II	Solid Tumour	Novotech	Cabrini	Gary Richardson			https://classic.clinicaltrials.gov/ct2/show/NCT05652855?term=MHB088C-CP001EN&draw=2&rank=1#eligibility			Melanoma	Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants with Advanced or Metastatic Solid Tumors	Yes			9/03/2023	MHB088C	MHB088C-CP001EN	0	5	1
Nuvation Bio - NUV-868-01 - CT1586	Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868-01	Phase I/II	Solid Tumour	Novotech	Cabrini	Shehara Mendis			https://classic.clinicaltrials.gov/ct2/show/NCT05252390?term=NUV-868-01&draw=2&rank=1			Melanoma	Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	Yes	21/08/2023		8/08/2023	Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	NUV-868-01	0	6	1
Nuvation Bio - NUV-868-01 - CT1586	Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868-01	Phase I/II	Solid Tumour	Novotech	PCCTU	Arun Azad	PCCTU MoncA Team	PCCTU MoncA	https://classic.clinicaltrials.gov/ct2/show/NCT05252390?term=NUV-868-01&draw=2&rank=1			Melanoma	Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	Yes			15/08/2023	Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	NUV-868-01	0	8	1
PIERRE FABRE AUSTRALIA PTY LTD - W00090GE303 / EORTC-2139-MG - COLUMBUS-AD CT1546	EORTC-2139-MG - COLUMBUS-AD Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group. W00090GE303	Phase III		PIERRE FABRE AUSTRALIA PTY LTD	Alfred - Medical Oncology	Andrew Haydon		ACT 2	https://classic.clinicaltrials.gov/ct2/show/NCT05270044?term=NCT05270044&draw=2&rank=1			Melanoma	Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group.	Yes	31/10/2022		20/10/2022	EORTC-2139-MG - COLUMBUS-AD	W00090GE303	1	10	1
PMCC Sponsored - 17/021 - CELEBRATE - NC229	CELEBRATE A Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF?mutant metastatic melanoma (The CELEBRATE study) 17/021	Phase I		Peter MacCallum Cancer Centre	Alfred - Medical Oncology	Mark Shackleton		ACT 2	https://classic.clinicaltrials.gov/ct2/show/NCT04720768?term=NCT04720768&draw=2&rank=1	RAF kinase, MEK 1/2 and CDK 4/6 inhibitors. VCA grant study, PMCC sponsored. Previous immunotherapy allowed. Investigator meeting will be set up to discuss recruitment and making study more accessible for patients. BRAF naive, or pre-treated - cannot put anyone one who has progressed on BRAF inihibitor.		Melanoma	A Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF?mutant metastatic melanoma (The CELEBRATE study)	Yes	11/05/2021		8/04/2021	CELEBRATE	17/021	3	4	1
PMCC sponsored - 20/044 - IMPARP-HRD - VC007	IMPARP-HRD An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects 20/044, VC007	Phase II	Solid Tumour	PMCC Sponsored	St Vincent's Hospital - Medical Oncology	Genni Newnham			https://clinicaltrials.gov/ct2/show/NCT04985721?term=NCT04985721&draw=2&rank=1			Melanoma	An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects	Yes	5/07/2022		5/07/2022	IMPARP-HRD	20/044, VC007	0		1
PharmaSols - MT-5111_001 - CT1464	5111_001 A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors MT - 5111_001	Phase I	Solid Tumour	Molecular Templates Inc	GVH	Arvind Sahu			https://classic.clinicaltrials.gov/ct2/show/NCT04029922?term=NCT04029922&draw=2&rank=1#eligibility	Stage: Metastatic Breast Cancer Tumour agnostic, HER2 altered Breast cancer expansion arm Must have HER2 expression on latest biopsy of a metastatic deposit Can be HER2 IHC2+ and non ISH-amplified Breast cancer cohort now in expansion Maximum tolerated dose reached in non-breast cohort		Melanoma	A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors	Yes	11/02/2022		11/02/2022	5111_001	MT - 5111_001	0	4	1
R2810-ONC-1788 CT1126	cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788	Phase III	Cutaneous SCC	Regeneron Pharmaceuticals	Bendigo	Sam Harris			https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility	Anti-PD-1 monoclonal antibody. Amendment underway to broaden the inclusion criteria. Recruitment slow.	Adjuvant	Melanoma	A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.	Yes	3/09/2020		24/06/2020	cPOST	R2810-ONC-1788	3	4	1
R2810-ONC-1788 CT1126	cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788	Phase III	Cutaneous SCC	Regeneron Pharmaceuticals	Bendigo	Sam Harris			https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility	Anti-PD-1 monoclonal antibody. Amendment underway to broaden the inclusion criteria. Recruitment slow.	Neo-adjuvant	Melanoma	A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.	Yes	3/09/2020		24/06/2020	cPOST	R2810-ONC-1788	3	4	1
Regeneron Inc - Harmony - R3767-ONC-2011 - CT1576	Harmony A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma R3767-ONC-2011	Phase III		ICON plc	Alfred - Medical Oncology	Andrew Haydon			https://classic.clinicaltrials.gov/ct2/show/NCT05352672?term=R3767-ONC-2011&draw=2&rank=1#eligibility		1st Line	Melanoma	A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma	Yes	19/01/2023		15/12/2022	Harmony	R3767-ONC-2011	1	8	1
Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126	cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788	Phase III	Cutaneous SCC	ICON Clinical Research	St Vincent's Hospital - Medical Oncology	Christopher Hart			https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility			Melanoma	A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.	Yes	31/10/2019		31/10/2019	cPOST	R2810-ONC-1788	0		1
Regeneron Pharmaceuticals - R3767-ONC-2055 - R3767ONC2055 - CT1662	R3767-ONC-2055 A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma R3767-ONC-2055	Phase III		ICON Clinical Research	Alfred - Medical Oncology	Andrew Haydon			https://clinicaltrials.gov/ct2/show/NCT05608291?term=R3767ONC2055&draw=2&rank=1			Melanoma	A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma	Yes			20/07/2023	R3767-ONC-2055	R3767-ONC-2055	0	15	1
RemeGen Co. - RC198-G001 - CT1604	CT1604 A Phase 1, First-in-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors RC198-G001	Phase I	Solid Tumour	Novotech	Cabrini	Gary Richardson			https://classic.clinicaltrials.gov/ct2/show/NCT05867303?term=RC198-G001&draw=2&rank=1			Melanoma	A Phase 1, First-in-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors	Yes	9/08/2023		26/07/2023	CT1604	RC198-G001	0	5	1
Servier - CL1-95012-001 - CT1463	CT1463 A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS CL1-95012-001	Phase I/II	Solid Tumour	Servier laboratories (AUST.)	Cabrini	Gary Richardson			https://classic.clinicaltrials.gov/ct2/show/NCT05159388?term=CL1-95012-001&draw=2&rank=1			Melanoma	A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS	Yes	3/06/2022		26/05/2022	CT1463	CL1-95012-001	1	5	1
St Vincents Hospital Sydney - NADOM - NC299	NADOM trial � Neoadjuvant/ Adjuvant trial of Darovasertib in Ocular Melanoma NADOM	Phase II		St Vincent�s Hospital Sydney Limited	Alfred - Medical Oncology	Mark Shackleton		ACT 2	https://classic.clinicaltrials.gov/ct2/show/NCT05187884?term=NADOM&draw=2&rank=1#eligibility			Melanoma	NADOM trial � Neoadjuvant/ Adjuvant trial of Darovasertib in Ocular Melanoma	Yes	14/07/2022		23/06/2022		NADOM	6		1
UPCOMING - BMS - CA052002 - CT1620	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors CA052002	Phase I/II	Solid Tumour	Bristol Myers Squibb	Cabrini	Anis Hamid			https://clinicaltrials.gov/ct2/show/NCT04895709?term=CA052-002&draw=2&rank=1			Melanoma	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors	Yes	14/08/2023		14/08/2023		CA052002	0	12	1
UPCOMING - Multitude Therapeutics - AMT11601 - CT1634	AMT-116-01 First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors AMT11601	Phase I	Solid Tumour	Multitude Therapeutics	Cabrini	Gary Richardson			https://classic.clinicaltrials.gov/ct2/show/NCT05725291?term=AMT116-01&draw=2&rank=1			Melanoma	First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors	Yes	22/09/2023		20/09/2023	AMT-116-01	AMT11601	0	6	1
	Study Details	Phase	Sub Therapeutic Area		Site

Melanoma – Upcoming Studies

Study Details:

Site:

Sub Therapeutic Area :

Phase:

s_external_protocol_id	Study Details	Site	s_treatment_stages	Therapeutic Area	Sub Therapeutic Area	s_recruitment_criteria	Sponsor	Phase	Team	Open To Accrual	Notes	PI	Study Coordinator	s_nick	s_other_id	Inclusion and Exclusion Criteria	Site Target	Total Recruitment
AMGEN - 20180144 - AMG144	AMG144 A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors 20180144	Monash Health - Oncology Department		Melanoma	Solid Tumour	A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors	Amgen	Phase I		Yes				AMG144	20180144	https://classic.clinicaltrials.gov/ct2/show/NCT04362748?term=NCT04362748&draw=2&rank=1		0
ANZMTG - 01.12 - EAGLE FM	EAGLE FM Inguinal or Ilio-inguinal Lymphadenectomy for patients with metastatic melanoma to groin lymph nodes and no evidence of pelvic disease on PET/CT Scan - A randomised phase III trial to evaluate survival, morbidity, and quality of life. 01.12	PMCC - Cancer Surgery Department		Melanoma		Inguinal or Ilio-inguinal Lymphadenectomy for patients with metastatic melanoma to groin lymph nodes and no evidence of pelvic disease on PET/CT Scan - A randomised phase III trial to evaluate survival, morbidity, and quality of life.	ANZMTG	Phase III		Yes				EAGLE FM	1.12	https://classic.clinicaltrials.gov/ct2/show/NCT02166788?term=NCT02166788&draw=2&rank=1		0
ANZMTG - 03.12 - MelMarT Trial	MelMarT Trial A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma. 03.12	PMCC - Cancer Surgery Department		Melanoma	Cutaneous SCC	A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma.	ANZMTG	Phase III		Yes				MelMarT Trial	3.12	https://classic.clinicaltrials.gov/ct2/show/NCT02385214?term=NCT02385214&draw=2&rank=1		0
ANZMTG - MSLT-II	A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node (Other IDs: CDR0000513043, JWCI-MORD-LM/SL-CLND-1102). MSLT-II	PMCC - Cancer Surgery Department		Melanoma		A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node (Other IDs: CDR0000513043, JWCI-MORD-LM/SL-CLND-1102).	ANZMTG	Phase III		Yes					MSLT-II	https://classic.clinicaltrials.gov/ct2/show/NCT00297895?term=NCT00389571&draw=2&rank=1		0
Akesobio - AK105-101	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors AK105-101	Border Medical Oncology		Melanoma	Solid Tumour	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors	Akesobio Australia Pty Ltd	Phase I		Yes					AK105-101	https://classic.clinicaltrials.gov/ct2/show/NCT03352531?term=NCT03352531&draw=2&rank=1		0
Akesobio - AK112-01	AK112-01 A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects with Advanced Solid Tumors AK112-01	Monash Health - Oncology Department		Melanoma	Solid Tumour	A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects with Advanced Solid Tumors	Akesobio	Phase I		Yes				AK112-01	AK112-01	https://classic.clinicaltrials.gov/ct2/show/NCT04047290?term=NCT04047290&draw=2&rank=1		0
Alkermes - ALK4230-A101 - ARTISTRY-1	ARTISTRY-1 A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1 ALK4230-A101	Border Medical Oncology		Melanoma	Renal Cell (Kidney)	A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1	Alkermes	Phase I/II		Yes				ARTISTRY-1	ALK4230-A101	https://classic.clinicaltrials.gov/ct2/show/NCT02799095?term=NCT02799095&draw=2&rank=1		0
Alkermes - ALK4230-A101 - ARTISTRY-1	ARTISTRY-1 A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1 ALK4230-A101	Border Medical Oncology		Melanoma	Solid Tumour	A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1	Alkermes	Phase I/II		Yes				ARTISTRY-1	ALK4230-A101	https://classic.clinicaltrials.gov/ct2/show/NCT02799095?term=NCT02799095&draw=2&rank=1		0
Arcus Biosciences - AB154CSP0001	A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Border Medical Oncology		Melanoma	Solid Tumour	A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Arcus Biosciences Australia Pty Ltd.	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT03628677?term=NCT03628677&draw=2&rank=1		0
Ascendis Pharma Oncology Division - TCTLR-101	Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Monash Health - Oncology Department		Melanoma	Solid Tumour	Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Ascendis Pharma Oncology Division A/S	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04799054?term=NCT04799054&draw=2&rank=1		0
BeiGene - BGB-900-105 - TIGIT	TIGIT Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors BGB-900-105	Monash Health - Oncology Department		Melanoma	Solid Tumour	Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Beigene	Phase Ib		Yes				TIGIT	BGB-900-105	https://classic.clinicaltrials.gov/ct2/show/NCT04047862?term=NCT04047862&draw=2&rank=1		0
BeiGene - BGB-900-105 - TIGIT	TIGIT Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors BGB-900-105	St Vincent's Hospital - Medical Oncology		Melanoma	Solid Tumour	Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Beigene	Phase Ib		Yes				TIGIT	BGB-900-105	https://classic.clinicaltrials.gov/ct2/show/NCT04047862?term=NCT04047862&draw=2&rank=1		0
BeiGene - BGB-A317-3111	A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Monash Health - Haematology Department		Melanoma	Solid Tumour	A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Beigene	Phase I/II		Yes						https://clinicaltrials.gov/ct2/show/NCT04282018?term=NCT04282018&draw=2&rank=1		0
BeiGene - BGB-A317-3111-10188-101	A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Monash Health - Oncology Department		Melanoma	Solid Tumour	A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Beigene	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04282018?term=NCT04282018&draw=1&rank=1		0
BeiGene - BGB-A317-A445-101 - OX40	Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Monash Health - Oncology Department		Melanoma	Solid Tumour	Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Beigene	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04215978?term=NCT04215978&draw=2&rank=1		0
BeiGene - ICP-CL-00303	A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations	Monash Health - Oncology Department		Melanoma	Solid Tumour	A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations	Beigene	Phase I/II		Yes						https://clinicaltrials.gov/ct2/show/NCT04565275?term=NCT04565275&draw=2&rank=1		0
Beigene - BGB-290-AU-102	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Eastern		Melanoma	Solid Tumour	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Beigene	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT03744468?term=NCT03744468&draw=2&rank=1		0
Binacea Pharma - BNA035-101	BNA035 A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors BNA035-101	St Vincent's Hospital - Medical Oncology		Melanoma	Solid Tumour	A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors	Binacea Pharma, Inc.	Phase I		Yes				BNA035	BNA035-101	https://classic.clinicaltrials.gov/ct2/show/NCT05150457?term=NCT05150457&draw=2&rank=1#eligibility		0
BioNTech SE - BNT111-01	Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma BNT111-01	Border Medical Oncology		Melanoma		Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma	BioNTech Cell & Gene Therapies GmbH	Phase II		Yes					BNT111-01	https://classic.clinicaltrials.gov/ct2/show/NCT04526899?term=NCT04526899&draw=2&rank=1		0
CCTG - ME.13 - STOP-GAP - UQ-QMP-0001 ME13	STOP-GAP A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma. ME.13	Eastern		Melanoma		A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma.	Melanoma And Skin Cancer	Phase III		Yes	PD-1 inhibitor. Lead site St Vincent's Sydney. ANZMTG study. Pembro and nivo ok, patients need to be on active treatment prior to randomisation. For pts who have reached maximum tumour response on immunotherapy. Standard of care study, with duration as intervention. Open and recruiting			STOP-GAP	ME.13	https://classic.clinicaltrials.gov/ct2/show/NCT02821013?term=NCT02821013&draw=2&rank=1		0
CCTG - UQ-QMP-0001 ME.13 - STOP-GAP	STOP-GAP A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma. ME.13	Monash Health - Oncology Department		Melanoma		A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma.	Melanoma And Skin Cancer	Phase III		Yes	PD-1 inhibitor. Lead site St Vincent's Sydney. ANZMTG study. Pembro and nivo ok, patients need to be on active treatment prior to randomisation. For pts who have reached maximum tumour response on immunotherapy. Standard of care study, with duration as intervention. Open and recruiting	Muhammad Alamgeer	Theresa Hosri	STOP-GAP	ME.13	https://classic.clinicaltrials.gov/ct2/show/NCT02821013?term=NCT02821013&draw=2&rank=1		0
CStone Pharmaceuticals - CS1003-101 - C-Stone	C-Stone A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors CS1003-101	Border Medical Oncology		Melanoma	Solid Tumour	A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors	CStone Pharmaceuticals	Phase I		Yes				C-Stone	CS1003-101	https://classic.clinicaltrials.gov/ct2/show/NCT03475251?term=NCT03475251&draw=2&rank=1		0
Canteen - ISRCTN36453794 - 2014-000259-99 - rEEcur	rEEcur International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma ISRCTN36453794	Monash Children's Cancer Centre		Melanoma	Sarcoma	International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma	Canteen - Australian Young Cancer Patient Clinical Trials Initiative	Phase II/III		Yes				rEEcur	ISRCTN36453794			0
Checkpoint Therapeutics - CK-301-101	CK-301-101 A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers CK-301-101	Eastern		Melanoma	Solid Tumour	A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers	Checkpoint Therapeutics, Inc.	Phase I		Yes				CK-301-101	CK-301-101	https://classic.clinicaltrials.gov/ct2/show/NCT03212404?term=NCT03212404&draw=2&rank=1		0
Corvus Pharmaceuticals - CPI-006-001	CPI-006-001 A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers CPI-006-001	Monash Health - Oncology Department		Melanoma	Solid Tumour	A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers	Corvus Pharmaceuticals, Inc	Phase I		Yes				CPI-006-001	CPI-006-001	https://classic.clinicaltrials.gov/ct2/show/NCT03454451?term=NCT03454451&draw=2&rank=1		0
ENB Therapeutics, Inc - MK3475-951 - ENB-003-101	ENB-003-101 A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors MK3475-951	Border Medical Oncology		Melanoma	Solid Tumour	A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors		Phase I/II		Yes				ENB-003-101	MK3475-951	https://classic.clinicaltrials.gov/ct2/show/NCT04205227?term=NCT04205227&draw=2&rank=1		0
Epimab - EMB02X101	A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors	Monash Health - Oncology Department		Melanoma	Solid Tumour	A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors	Shanghai EpimAb Biotherapeutics Co., Ltd.	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04618393?term=NCT04618393&draw=2&rank=1		0
GSK - BRF115532 - CDRB436F2301 - COMBI-AD - CT546	COMBI-AD A phase III randomized double blind study of dabrafenib (GSK2118436) in combination with trametinib (GSK1120212) versus placebo in the adjuvant treatment of high-risk BRAF V600 mutation-positive cutaneous melanoma after surgical resection. CDRB436F2301	Eastern		Melanoma		A phase III randomized double blind study of dabrafenib (GSK2118436) in combination with trametinib (GSK1120212) versus placebo in the adjuvant treatment of high-risk BRAF V600 mutation-positive cutaneous melanoma after surgical resection.	GlaxoSmithKline (GSK)	Phase III		Yes				COMBI-AD	CDRB436F2301	https://classic.clinicaltrials.gov/ct2/show/NCT01682083?term=NCT01682083&draw=2&rank=1		0
Genentech - GO43712	A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors GO43712	Border Medical Oncology		Melanoma	Solid Tumour	A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Genentech	Phase I		Yes					GO43712	https://classic.clinicaltrials.gov/ct2/show/NCT05487235?term=NCT05487235&draw=2&rank=1		0
Haihe Biopharma - CYH33-G102	Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Monash Health - Oncology Department		Melanoma	Solid Tumour	Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Haihe Biopharma Co., Ltd.	Phase Ib		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04586335?term=NCT04586335&draw=1&rank=1		0
IO Biotech - IO102-IO103-013 (IOB-013) / MK3475-D18 (KN-D18) - CT1481	MK3475-D18 (KN-D18) An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma IO102-IO103-013	Border Medical Oncology		Melanoma		An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma	IO Biotech APS	Phase III		Yes				MK3475-D18 (KN-D18)	IO102-IO103-013	https://classic.clinicaltrials.gov/ct2/show/NCT05155254?term=NCT05155254&draw=2&rank=1		0
Idera Pharmaceuticals - 2125-MEL-301 - ILLUMINATE-301	ILLUMINATE-301 A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma 2125-MEL-301	Eastern		Melanoma		A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma	Idera Pharmaceuticals, Inc.	Phase III		Yes				ILLUMINATE-301	2125-MEL-301	https://classic.clinicaltrials.gov/ct2/show/NCT03445533?term=NCT03445533&draw=2&rank=1		0
Ignyta - RXDX-101-02 - STARTRK-2	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Border Medical Oncology		Melanoma	Solid Tumour	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Ignyta, Inc.	Phase II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02568267?term=NCT02568267&draw=2&rank=1		0
Janssen-Cilag - CR108661 - RAGNAR	RAGNAR A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations CR108661	St Vincent's Hospital - Medical Oncology		Melanoma	Solid Tumour	A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations	Janssen Cilag	Phase II		Yes				RAGNAR	CR108661	https://classic.clinicaltrials.gov/ct2/show/NCT04083976?term=NCT04083976&draw=2&rank=1#eligibility		0
LaNova - LM302-01-201	LANOVA A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors LM302-01-201	Monash Health - Oncology Department		Melanoma	Solid Tumour	A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors	LaNova Australia	Phase I/II		Yes				LANOVA	LM302-01-201	https://classic.clinicaltrials.gov/ct2/show/NCT05188664?term=NCT05188664&draw=2&rank=1		0
Lawson Health - R-11-605 - SABR-COMET	SABR-COMET Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial R-11-605	Alfred Health - Radiation Oncology Department		Melanoma		Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial	Lawson Health Research Institute	Phase II		Yes				SABR-COMET	R-11-605	https://classic.clinicaltrials.gov/ct2/show/NCT01446744?term=NCT01446744&draw=2&rank=1		0
Merck - MK-1084 - MK-1084-001	1084-001 A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors MK-1084-001	Monash Health - Oncology Department		Melanoma	Solid Tumour	A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors	Merck	Phase I		Yes				1084-001	MK-1084-001	https://classic.clinicaltrials.gov/ct2/show/NCT05067283?term=NCT05067283&draw=2&rank=1		0
Merck - MK-7339-007 - KEYLYNK-007	KEYLYNK-007 A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer MK-7339-007	Monash Health - Oncology Department		Melanoma	Solid Tumour	A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer	Merck	Phase II		Yes				KEYLYNK-007	MK-7339-007	https://classic.clinicaltrials.gov/ct2/show/NCT04123366?term=NCT04123366&draw=2&rank=1		0
Merck - MK-7902-004 - LEAP-004	LEAP-004 A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent MK-7902-004	Eastern		Melanoma		A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent	Merck	Phase II		Yes				LEAP-004	MK-7902-004	https://classic.clinicaltrials.gov/ct2/show/NCT03776136?term=NCT03776136&draw=2&rank=1		0
Merck - MK475-054 - 1325-MG - KEYNOTE-054	KEYNOTE-054 Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK- 3475) Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group MK475-054	Eastern		Melanoma		Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK- 3475) Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group	Merck	Phase III		Yes				KEYNOTE-054	MK475-054	https://classic.clinicaltrials.gov/ct2/show/NCT02362594?term=NCT02362594&draw=2&rank=1		0
Molecular Templates - MT - 5111_001	5111_001 A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors MT-5111_001	St Vincent's Hospital - Medical Oncology		Melanoma	Solid Tumour	A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors	Molecular Templates Inc	Phase I/II		Yes	Tumour agnostic, HER2 altered Breast cancer expansion arm Must have HER2 expression on latest biopsy of a metastatic deposit Can be HER2 IHC2+ and non ISH-amplified Breast cancer cohort now in expansion Maximum tolerated dose reached in non-breast cohort			5111_001	MT-5111_001	https://classic.clinicaltrials.gov/ct2/show/NCT04029922?term=NCT04029922&draw=2&rank=1#eligibility		0
Monash University - SABR-IMPACT I	Treating metastatic melanoma with Stereotactic Ablative Radiotherapy and Immune Pathway ACTivation: A phase I dose-escalation trial (SABR IMPACT I)	Alfred Health - Radiation Oncology Department		Melanoma		Treating metastatic melanoma with Stereotactic Ablative Radiotherapy and Immune Pathway ACTivation: A phase I dose-escalation trial (SABR IMPACT I)	Monash University	Phase I		Yes								0
No CTA Finance - AMGEN - 20110265 - MASTERKEY-265 - CT682	MASTERKEY-265 A Phase Ib/III, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma	Austin Health		Melanoma		A Phase Ib/III, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma	Amgen	Phase III		Yes				MASTERKEY-265		https://clinicaltrials.gov/ct2/show/NCT02263508?term=NCT02263508&draw=2&rank=1		0
No CTA Finance - AMGEN - 20110266 - 2014-001146-13	A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma	Austin Health		Melanoma		A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma	Amgen	Phase II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02211131?term=NCT02211131&draw=2&rank=1		0
No CTA Finance - APG-115-US-002	A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors	Austin Health		Melanoma	Uveal	A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors	Ascentage	Phase Ib/II		Yes	Any line, not just first. Likely open for a only a few more months. Has a mucosal cohort.	Damien Kee	CCTC Team 1			https://clinicaltrials.gov/ct2/show/record/NCT03611868?term=NCT03611868&draw=2&rank=1		0
No CTA Finance - Abbvie - M16-438	A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands	Austin Health		Melanoma	Solid Tumour	A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands	AbbVie	Phase I		Yes						https://clinicaltrials.gov/ct2/show/record/NCT03234712?term=NCT03234712&draw=2&rank=1		0
No CTA Finance - Akeso - AK117-101	A Phase 1, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 in Subjects With Relapsed/Refractory Advanced or Metastatic Solid Tumors or Lymphomas	Austin Health		Melanoma	Solid Tumour	A Phase 1, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 in Subjects With Relapsed/Refractory Advanced or Metastatic Solid Tumors or Lymphomas	Akesobio Australia Pty Ltd	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04349969?term=NCT04349969&draw=2&rank=1		0
No CTA Finance - Akesobio Australia Pty Ltd - AK104-101 - CT934	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors	Austin Health		Melanoma	Solid Tumour	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors	Akesobio Australia Pty Ltd	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT03261011?term=NCT03261011&draw=2&rank=1		0
No CTA Finance - Antengene - ATG-017-001 - ERASER	ERASER A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients With Advanced Solid Tumors and Hematological Malignancies	Austin Health		Melanoma	Solid Tumour	A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients With Advanced Solid Tumors and Hematological Malignancies	Antengene (AUS) PTY. LTD	Phase I		Yes				ERASER		https://clinicaltrials.gov/ct2/show/NCT04305249?term=NCT04305249&draw=2&rank=1		0
No CTA Finance - Antengene - ATG-101-001 - PROBE - CT1471	PROBE A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas ATG-101-001	Austin Health		Melanoma	Solid Tumour	A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas		Phase I		Yes				PROBE	ATG-101-001	https://clinicaltrials.gov/ct2/show/NCT04986865?term=NCT04986865&draw=2&rank=1		0
No CTA Finance - Arcus Biosciences - AB154CSP0001	A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Austin Health		Melanoma	Solid Tumour	A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Arcus Biosciences Australia Pty Ltd.	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT03628677?term=NCT03628677&draw=2&rank=1		0
No CTA Finance - BMS - CA030-001	A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors.	Austin Health		Melanoma	Solid Tumour	A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors.	BMS	Phase I/II		Yes	Anti-CTLA-4 monoclonal antibody. Melanoma cohort	Damien Kee	CCTC Team 1			https://clinicaltrials.gov/ct2/show/study/NCT03369223?term=NCT03369223&draw=2&rank=1		0
No CTA Finance - BMS - CA031-002 - TIM-3	A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors	Austin Health		Melanoma	Solid Tumour	A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors	Bristol-Myers Squibb (BMS)	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT03446040?term=NCT03446040&draw=2&rank=1		0
No CTA Finance - BMS - CA209-067 - CheckMate 238 - CT623	CheckMate 238 A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma CA209-067	Austin Health		Melanoma		A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma	Bristol-Myers Squibb (BMS)	Phase III		Yes				CheckMate 238	CA209-067	https://classic.clinicaltrials.gov/ct2/show/NCT01844505?term=NCT01844505&draw=2&rank=1		0
No CTA Finance - BMS - CA209-067 - CheckMate 238 - CT623	CheckMate 238 A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma CA209-067	Eastern		Melanoma		A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma	Bristol-Myers Squibb (BMS)	Phase III		Yes				CheckMate 238	CA209-067	https://classic.clinicaltrials.gov/ct2/show/NCT01844505?term=NCT01844505&draw=2&rank=1		0
No CTA Finance - BMS - CA209-238 - CheckMate 238 - CT748	A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence	Austin Health		Melanoma		A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence	Bristol-Myers Squibb (BMS)	Phase III		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02388906?term=NCT02388906&draw=2&rank=1		0
No CTA Finance - BMS - CA224098 - RELATIVITY-098 - CT1462	RELATIVITY-098 A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma CA224098	Austin Health		Melanoma		A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma	Bristol-Myers Squibb (BMS)	Phase III		Yes		Damien Kee	CCTC Team 1	RELATIVITY-098	CA224098	https://clinicaltrials.gov/ct2/show/NCT05002569?term=NCT05002569&draw=2&rank=1		0
No CTA Finance - BeiGene - BGB-A317-3111	A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Austin Health		Melanoma	Solid Tumour	A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Beigene	Phase I/II		Yes						https://clinicaltrials.gov/ct2/show/NCT04282018?term=NCT04282018&draw=2&rank=1		0
No CTA Finance - BeiGene - ICP-CL-00303	A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations	Austin Health		Melanoma	Solid Tumour	A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations	Beigene	Phase I/II		Yes						https://clinicaltrials.gov/ct2/show/NCT04565275?term=NCT04565275&draw=2&rank=1		0
No CTA Finance - CStone - CS3005-101	A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors	Austin Health		Melanoma	Solid Tumour	A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors		Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04233060?term=NCT04233060&draw=2&rank=1		0
No CTA Finance - Five Prime Therapeutics - FPT155-001 - CT1051	A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors	Austin Health		Melanoma	Solid Tumour	A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors	Five Prime Therapeutics, Inc.	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04074759?term=NCT04074759&draw=2&rank=1		0
No CTA Finance - GSK - BRF115532 - CDRB436F2301 - COMBI-AD - CT546	COMBI-AD A phase III randomized double blind study of dabrafenib (GSK2118436) in combination with trametinib (GSK1120212) versus placebo in the adjuvant treatment of high-risk BRAF V600 mutation-positive cutaneous melanoma after surgical resection. CDRB436F2301	Austin Health		Melanoma		A phase III randomized double blind study of dabrafenib (GSK2118436) in combination with trametinib (GSK1120212) versus placebo in the adjuvant treatment of high-risk BRAF V600 mutation-positive cutaneous melanoma after surgical resection.	GlaxoSmithKline (GSK)	Phase III		Yes				COMBI-AD	CDRB436F2301	https://classic.clinicaltrials.gov/ct2/show/NCT01682083?term=NCT01682083&draw=2&rank=1		0
No CTA Finance - GSK - GSK204691 - INDUCE-1	A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors	Austin Health		Melanoma	Solid Tumour	A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors	GlaxoSmithKline (GSK)	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02723955?term=NCT02723955&draw=2&rank=1		0
No CTA Finance - Harbour Biomed - 4003.1 - CT1167	A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors	Austin Health		Melanoma	Solid Tumour	A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors	Harbour BioMed (Guangzhou) Co. Ltd	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04135261?term=NCT04135261&draw=2&rank=1		0
No CTA Finance - Ignyta - RXDX-101-02 - STARTRK-2	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Austin Health		Melanoma	Solid Tumour	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Ignyta, Inc.	Phase II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02568267?term=NCT02568267&draw=2&rank=1		0
No CTA Finance - MacroGenics - CP-MGD009-01	Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms	Austin Health		Melanoma	Solid Tumour	Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms	Macrogenics Inc.	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02628535?term=NCT02628535&draw=2&rank=1		0
No CTA Finance - Merck - MK3475-006 - 2012-004907-10	A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma	Austin Health		Melanoma		A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma	Merck	Phase III		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT01866319?term=NCT01866319&draw=2&rank=1		0
No CTA Finance - Merck - MK3475-029 - KEYNOTE 029	A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)	Austin Health		Melanoma	Renal Cell (Kidney)	A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)	Merck	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02089685?term=NCT02089685&draw=2&rank=1		0
No CTA Finance - Nektar Therapeutics - CA045-022 - 20-214-29 - PIVOT-12 - CT1347	A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)	Austin Health		Melanoma		A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)		Phase III		Yes						https://clinicaltrials.gov/ct2/show/NCT04410445?term=NCT04410445&draw=2&rank=1		0
No CTA Finance - Novartis - CLAG525X2101C - LAG525	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Austin Health		Melanoma	Bladder	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Novartis Pharmaceuticals Australia Pty Limited	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&draw=2&rank=1		0
No CTA Finance - Novartis - CLAG525X2101C - LAG525	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Austin Health		Melanoma	Cutaneous SCC	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Novartis Pharmaceuticals Australia Pty Limited	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&draw=2&rank=1		0
No CTA Finance - Novartis - CLAG525X2101C - LAG525	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Austin Health		Melanoma	Prostate	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Novartis Pharmaceuticals Australia Pty Limited	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&draw=2&rank=1		0
No CTA Finance - Novartis - CLAG525X2101C - LAG525	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Austin Health		Melanoma	Renal Cell (Kidney)	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Novartis Pharmaceuticals Australia Pty Limited	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&draw=2&rank=1		0
No CTA Finance - Novartis - CLAG525X2101C - LAG525	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Austin Health		Melanoma	Solid Tumour	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Novartis Pharmaceuticals Australia Pty Limited	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&draw=2&rank=1		0
No CTA Finance - Novotech - HBI-8000-303 - CT1341	HUYA A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI 8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors HBI-8000-303 [CT1341]	Grampians Health	2nd Line	Melanoma		HUYA A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI 8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors HBI-8000-303 [CT1341]	Novotech	Phase III		Yes		Sharad Sharma						0
No CTA Finance - PIERRE FABRE - W00090GE303 / EORTC-2139-MG - COLUMBUS-AD - CT1546	EORTC-2139-MG - COLUMBUS-AD Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group. W00090GE303	Austin Health		Melanoma		Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group.		Phase III		Yes				EORTC-2139-MG - COLUMBUS-AD	W00090GE303	https://classic.clinicaltrials.gov/ct2/show/NCT05270044?term=NCT05270044&draw=2&rank=1		0
No CTA Finance - PMCC Sponsored - 17/021 - CELEBRATE - NC229	CELEBRATE A Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF?mutant metastatic melanoma. 17/021	Austin Health		Melanoma		A Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF?mutant metastatic melanoma.	PMCC Sponsored	Phase I		Yes	RAF kinase, MEK 1/2 and CDK 4/6 inhibitors. VCA grant study, PMCC sponsored. Previous immunotherapy allowed. Investigator meeting will be set up to discuss recruitment and making study more accessible for patients. BRAF naive, or pre-treated - cannot put anyone one who has progressed on BRAF inihibitor.			CELEBRATE	17/021	https://classic.clinicaltrials.gov/ct2/show/NCT04720768?term=NCT04720768&draw=2&rank=1		0
No CTA Finance - Pfizer - B9991004 - JAVELIN Medley	A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies	Austin Health		Melanoma		A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies	Pfizer Australia Pty Ltd	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT02554812?term=NCT02554812&draw=2&rank=1		0
No CTA Finance - RAPT Therapeutics - FLX475-02	Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer	Austin Health		Melanoma		Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer	RAPT Therapeutics, Inc.	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT03674567?term=NCT03674567&draw=2&rank=1		0
No CTA Finance - Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126	cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788	Border Medical Oncology		Melanoma	Cutaneous SCC	A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.	Regeneron Pharmaceuticals	Phase III		Yes	Anti-PD-1 monoclonal antibody.	Richard Eek		cPOST	R2810-ONC-1788	https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility		0
No CTA Finance - Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126	cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788	Austin Health		Melanoma	Cutaneous SCC	A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.	Regeneron Pharmaceuticals	Phase III		Yes	Anti-PD-1 monoclonal antibody.	Hui Gan		cPOST	R2810-ONC-1788	https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility		0
No CTA Finance - Sanofi - ACT16845 - Pegathor Skin 201	A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers	Austin Health		Melanoma	Cutaneous SCC	A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers	Sanofi-Aventis	Phase I/II		Yes	Open at Austin after temporarily on internal hold due to drug requiring HDU support. No patients on at Austin as of yet.	Damien Kee	CCTC Team 1			https://clinicaltrials.gov/ct2/show/NCT04913220?term=ACT16845&draw=2&rank=1		0
No CTA Finance - Sanofi - TCD14678 - CT1112	A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors	Austin Health		Melanoma	Colorectal	A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors	Sanofi-Aventis	Phase Ib		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT03192345?term=NCT03192345&draw=2&rank=1		0
No CTA Finance -Incyte - INCB99280-112	A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors	Austin Health		Melanoma	Solid Tumour	A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors	Incyte Corporation	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04242199?term=NCT04242199&draw=2&rank=1		0
OncoSec Medical Incorporation - OMS-I103 - The PISCES Study- Keynote 695	A Multicenter Phase 2, Open-Label Trial of Intratumoral pIL-12 Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment	Eastern		Melanoma		A Multicenter Phase 2, Open-Label Trial of Intratumoral pIL-12 Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment	OncoSec Medical Incorporated	Phase II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT03132675?term=NCT03132675&draw=2&rank=1		0
PMCC Sponsored - 17/021 - CELEBRATE - NC229	CELEBRATE A Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF?mutant metastatic melanoma. 17/021	Eastern		Melanoma		A Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF?mutant metastatic melanoma.	PMCC Sponsored	Phase I		Yes	RAF kinase, MEK 1/2 and CDK 4/6 inhibitors. VCA grant study, PMCC sponsored. Previous immunotherapy allowed. Investigator meeting will be set up to discuss recruitment and making study more accessible for patients. BRAF naive, or pre-treated - cannot put anyone one who has progressed on BRAF inihibitor.			CELEBRATE	17/021	https://classic.clinicaltrials.gov/ct2/show/NCT04720768?term=NCT04720768&draw=2&rank=1		0
PMCC Sponsored - PMC67199 - PARLuNET	Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	PMCC - Molecular Imaging Department		Melanoma	Neuroendocrine	Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	PMCC Sponsored	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT05053854?term=NCT05053854&draw=2&rank=1		0
PMCC Sponsored - PMC67199 - PARLuNET	Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	PMCC - Molecular Imaging Department		Melanoma	Pancreatic	Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	PMCC Sponsored	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT05053854?term=NCT05053854&draw=2&rank=1		0
PMCC Sponsored - PMC67199 - PARLuNET	Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	PMCC - Molecular Imaging Department		Melanoma	Sarcoma	Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	PMCC Sponsored	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT05053854?term=NCT05053854&draw=2&rank=1		0
PMCC Sponsored - U1111-1156-8748 - FSRT - EYE STUDY	Can reduced dose radiotherapy delivered in standard fractionation improve the therapeutic index for stereotactic treatment of juxtapapillary choroidal melanoma?	PMCC - Moorabbin / Radiation Oncology		Melanoma		Can reduced dose radiotherapy delivered in standard fractionation improve the therapeutic index for stereotactic treatment of juxtapapillary choroidal melanoma?	PMCC Sponsored	Phase 0/I		Yes								0
PMCC sponsored - 20/044 - IMPARP-HRD - VC007	IMPARP-HRD An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects 20/044, VC007	Austin Health		Melanoma	Solid Tumour	An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects	PMCC Sponsored	Phase II		Yes				IMPARP-HRD	20/044, VC007	https://clinicaltrials.gov/ct2/show/NCT04985721?term=NCT04985721&draw=2&rank=1		0
Pfizer - C4221011 - ARRAY 165-112	A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma	Monash Children's Cancer Centre		Melanoma		A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma	Pfizer Australia Pty Ltd	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT03878719?term=NCT03878719&draw=2&rank=1		0
Replimune - RPL-002-18 - CERPASS	CERPASS A Randomized, Controlled, Open-label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma. RPL-002-18	Monash Health - Oncology Department		Melanoma	Cutaneous SCC	A Randomized, Controlled, Open-label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma.	Replimune Inc.	Phase II		Yes	Anti-PD-1 monoclonal antibody + oncolytic virus. For pts with injectable disease.	Muhammad Alamgeer		CERPASS	RPL-002-18	https://classic.clinicaltrials.gov/ct2/show/NCT04050436?term=NCT04050436&draw=2&rank=1		0
Senz Oncology - EOHC-1001-01	An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.	Monash Health - Oncology Department		Melanoma	Other	An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.	Senz Oncology	Phase I/II		Yes								0
TROG - 2009/039 - 01.09 - RTN2	A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck	PMCC - Cancer Surgery Department		Melanoma	Other	A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck	TROG	Phase III		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT00975520?term=NCT00975520&draw=2&rank=1		0
TROG - TROG 08.09 - 2009/039 - RTN2	A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (Other IDs: TROG 08.09, 2009/039, ANZMTG 01.09)	Alfred Health - Radiation Oncology Department		Melanoma		A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (Other IDs: TROG 08.09, 2009/039, ANZMTG 01.09)	TROG	Phase III		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT00975520?term=NCT00975520&draw=2&rank=1		0
Takeda - TAK-280-1501	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Monash Health - Oncology Department		Melanoma	Solid Tumour	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Takeda Oncology	Phase I/II		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT05220098?term=NCT05220098&draw=2&rank=1		0
UPCOMING - Abbvie - M23-385 - CT	M23-385 A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors M23-385	PCCTU		Melanoma	Solid Tumour	A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors	Parexel	Phase I	PCCTU MoncC	Yes		Michael Michael	PCCTU MoncC Team	M23-385	M23-385	https://classic.clinicaltrials.gov/ct2/show/NCT05599984?term=M23-385&draw=2&rank=1#eligibility	10	0
UPCOMING - Allucent - RMC-6291-001 - CT	Allucent Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors RMC-6291-001	SWH		Melanoma	Solid Tumour	Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors		Phase Ib/II		Yes		Theresa Hayes		Allucent	RMC-6291-001	https://clinicaltrials.gov/ct2/show/NCT05462717?term=RMC-6291-001&draw=2&rank=1		0
UPCOMING - Anwita Biosciences - AWT020001 - CT	AWT020001 A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer AWT020001	Alfred - Medical Oncology		Melanoma	Solid Tumour	A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer	IQVIA	Phase I/II		Yes		Mark Voskoboynik		AWT020001	AWT020001		8	0
UPCOMING - AstraZeneca - D8470C00001 - CYAD-1 - CT	CYAD-1 A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants with Selected Advanced or Metastatic Solid Tumors. D8470C00001	PCCTU		Melanoma	Solid Tumour	A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants with Selected Advanced or Metastatic Solid Tumors.	AstraZeneca	Phase I/IIa	PCCTU Breast	Yes		Stephen Luen	PCCTU Breast Team	CYAD-1	D8470C00001		10	0
UPCOMING - Bendigo Sponsored - OPTION - NC	OligoProgressive Treatment for ImmunOtherapy patieNts (OPTION) OPTION	Bendigo		Melanoma		OligoProgressive Treatment for ImmunOtherapy patieNts (OPTION)	Bendigo Health	N/A		Yes		Sam Harris			OPTION		33	0
UPCOMING - Genentech - GO44431 - CT	A phase I, open label, multicenter, dose escalation study evaluating the safety, pharmacokinetics, and activity of RO7566802 as a single agent and in combination with Atezolizumab in patients with locally advanced or metastatic solid tumors GO44431	PCCTU		Melanoma	Solid Tumour	A phase I, open label, multicenter, dose escalation study evaluating the safety, pharmacokinetics, and activity of RO7566802 as a single agent and in combination with Atezolizumab in patients with locally advanced or metastatic solid tumors	PPD Australia Pty Ltd	Phase I		Yes		Ben Tran			GO44431		12	0
UPCOMING - George Clinical - AT-0174-001 - Antido - CT	Antido A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies AT-0174-001	Grampians Health		Melanoma	Solid Tumour	A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	The George Institute	Phase I		Yes		Lizzie Lim		Antido	AT-0174-001		3	0
UPCOMING - Gilead - GS-US-521-6317 - CT	A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti�PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors GS-US-521-6317	PCCTU		Melanoma	Solid Tumour	A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti�PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors	Gilead Sciences Pty Ltd	Phase I	PCCTU EDD	Yes		Jayesh Desai	PCCTU EDD Team		GS-US-521-6317		10	0
UPCOMING - IDEAYA - IDE196009 - DAR-UM-09 - CT	DAR-UM-09 (Neo)adjuvant IDE196 in patients with localized ocular melanoma [DAR-UM-09]	Alfred - Medical Oncology		Melanoma		(Neo)adjuvant IDE196 in patients with localized ocular melanoma [DAR-UM-09]	Southern Star Research			Yes		Mark Shackleton		DAR-UM-09				0
UPCOMING - IO Biotech - IO102-IO 103-032 - IOB?032/PN?E40	IOB?032/PN?E40 Phase II, multi?cohort trial of neoadjuvant and post?surgery IO102?IO103 and pembrolizumab in patients with selected resectable tumors IO102-IO 103-032	PCCTU		Melanoma	Cutaneous SCC	Phase II, multi?cohort trial of neoadjuvant and post?surgery IO102?IO103 and pembrolizumab in patients with selected resectable tumors	Accelagen	Phase II	PCCTU MoncC	Yes		Annette Lim	PCCTU MoncC Team	IOB?032/PN?E40	IO102-IO 103-032	https://classic.clinicaltrials.gov/ct2/show/NCT05280314?term=IO102-IO+103-032&draw=2&rank=1	2	0
UPCOMING - Immunocore - IMCF106C101 - CT	A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers IMCF106C101	Alfred - Medical Oncology		Melanoma	Solid Tumour	A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers	IQVIA	Phase I/II		Yes		Mark Voskoboynik			IMCF106C101	https://clinicaltrials.gov/ct2/show/record/NCT04262466?term=PRAME-Positive&draw=2&rank=1	3	0
UPCOMING - Immunocore - IMCgp100-203 - TEBE-AM - CT	TEBE-AM Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator�s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM) IMCgp100-203	Alfred - Medical Oncology		Melanoma		Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator�s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)	IQVIA	Phase II/III		Yes		Malaka Ameratunga		TEBE-AM	IMCgp100-203	https://classic.clinicaltrials.gov/ct2/show/NCT05549297?term=IMCgp100-203&draw=2&rank=1	3	0
UPCOMING - Incyte - INCB161734-101 - CT	INCB161734-101 A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB161734-101	Alfred - Medical Oncology		Melanoma	Solid Tumour	A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	IQVIA	Phase I		Yes				INCB161734-101	INCB161734-101			0
UPCOMING - Incyte - INCB161734-101 - CT	INCB161734-101 A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB161734-101	PCCTU		Melanoma	Solid Tumour	A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	IQVIA	Phase I	PCCTU EDD	Yes		Jayesh Desai	PCCTU EDD Team	INCB161734-101	INCB161734-101		10	0
UPCOMING - Iovance - IOV-MEL-301 - TILVANCE-301	TILVANCE-301 A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma IOV-MEL-301	PCCTU		Melanoma		A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma	PPD Australia Pty Ltd	Phase III	PCCTU MoncC	Yes		Lavinia Spain	PCCTU MoncC Team	TILVANCE-301	IOV-MEL-301	https://classic.clinicaltrials.gov/ct2/show/NCT05727904?term=IOV-MEL-301&draw=2&rank=1	4	0
UPCOMING - MSD - F11-00 - MK-3475A-F11-00	MK-3475A-F11 A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types F11-00	Peninsula Health		Melanoma	Solid Tumour	A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types	Merck Sharp & Dohme (MSD)	Phase II		Yes		Joanne Lundy		MK-3475A-F11	F11-00			0
UPCOMING - MSD - MK4280A-010 - CT	MK4280A-010 A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors 010-00	Alfred - Medical Oncology		Melanoma	Solid Tumour	A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors	Merck Sharp & Dohme (MSD)	Phase II		Yes		Mark Voskoboynik		MK4280A-010	010-00	https://classic.clinicaltrials.gov/ct2/show/NCT06036836?term=MK4280A-010&draw=2&rank=1#eligibility	4	0
UPCOMING - Multitude - 322/23 - AMT11601 - CT	AMT-116-01 First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors AMT11601	Alfred - Medical Oncology		Melanoma	Solid Tumour	First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors	IQVIA	Phase I		Yes		Mark Voskoboynik		AMT-116-01	AMT11601	https://classic.clinicaltrials.gov/ct2/show/NCT05725291?term=AMT116-01&draw=2&rank=1	6	0
UPCOMING - Novotech - MTX-TROP2-302 - MYE Symphony	MYE Symphony A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults with Advanced or Metastatic Epithelial Tumors MTX-TROP2-302	Cabrini		Melanoma	Solid Tumour	A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults with Advanced or Metastatic Epithelial Tumors	Novotech	Phase I		Yes		Gary Richardson		MYE Symphony	MTX-TROP2-302	https://classic.clinicaltrials.gov/ct2/show/NCT05969041?term=MTX-TROP2-302&draw=2&rank=1#eligibility		0
UPCOMING - PIERRE FABRE AUSTRALIA PTY LTD - W00090GE303 / EORTC-2139-MG - COLUMBUS-AD CT1546	EORTC-2139-MG - COLUMBUS-AD Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group. W00090GE303	Bendigo		Melanoma		Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group.	PIERRE FABRE AUSTRALIA PTY LTD	Phase III		Yes		Sam Harris		EORTC-2139-MG - COLUMBUS-AD	W00090GE303	https://classic.clinicaltrials.gov/ct2/show/NCT05270044?term=NCT05270044&draw=2&rank=1	10	0
UPCOMING - PMCC - Cancer Statewide_26072023 - NC	Cancer Statewide A hybrid type III effectiveness and implementation trial of complex genomic profiling in patients with advanced cancer using three models of care in metropolitan and regional oncology centres in Victoria, Australia Cancer Statewide_26072023	LRH		Melanoma	Other	A hybrid type III effectiveness and implementation trial of complex genomic profiling in patients with advanced cancer using three models of care in metropolitan and regional oncology centres in Victoria, Australia	PMCC Sponsored	Phase III		Yes		Sachin Joshi		Cancer Statewide	Cancer Statewide_26072023		40	0
UPCOMING - PPD - BLU-222-1101 - VELA - CT1563	VELA A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors BLU-222-1101	PCCTU		Melanoma	Solid Tumour	A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors	PPD Australia Pty Ltd	Phase I/II	PCCTU Gynae	Yes		George Au-Yeung		VELA	BLU-222-1101	https://clinicaltrials.gov/ct2/show/NCT05252416?term=BLU-222-1101&draw=2&rank=1	8	0
UPCOMING - Servier - CL1-95012-001 - CT1463	CT1463 A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS CL1-95012-001	PCCTU		Melanoma	Solid Tumour	A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS	Servier laboratories (AUST.)	Phase I/II	PCCTU Gynae	Yes		Linda Mileshkin	PCCTU Gynae Team	CT1463	CL1-95012-001	https://classic.clinicaltrials.gov/ct2/show/NCT05159388?term=CL1-95012-001&draw=2&rank=1	5	0
UPCOMING - Tigermed - AMT-253-01 - AMT253-01	AMT253-01 First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors AMT-253-01	Cabrini		Melanoma	Solid Tumour	First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors	Tigermed	Phase I		Yes				AMT253-01	AMT-253-01	https://classic.clinicaltrials.gov/ct2/show/NCT05906862?term=AMT-253-01&draw=2&rank=1		0
UPCOMING - Tigermed - AMT-253-01 - AMT253-01 - CT	AMT253-01 First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors AMT-253-01	Alfred - Medical Oncology		Melanoma	Solid Tumour	First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors	Tigermed	Phase I		Yes		Andrew Haydon		AMT253-01	AMT-253-01	https://classic.clinicaltrials.gov/ct2/show/NCT05906862?term=AMT-253-01&draw=2&rank=1	5	0
University Hospital Muenster - EE08 - EWING 2008 - 108128 - NC92	Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma.	Monash Children's Cancer Centre		Melanoma	Sarcoma	Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma.	University Hospital Muenster	Phase III		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT00987636?term=NCT00987636&draw=2&rank=1		0
Vivace - VT3989-001	Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene	Monash Health - Oncology Department		Melanoma	Solid Tumour	Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene	Vivace Therapeutics, Inc	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04665206?term=NCT04665206&draw=2&rank=1		0
Wellmarker Bio - WMS1030-101 - WM-S1-030	A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors	Monash Health - Oncology Department		Melanoma	Solid Tumour	A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors	Wellmarker Bio	Phase I		Yes						https://classic.clinicaltrials.gov/ct2/show/NCT04801095?term=NCT04801095&draw=2&rank=1		0
	Study Details	Site			Sub Therapeutic Area			Phase

Tumour Group Report – Melanoma

Melanoma – Open Studies

Melanoma – Upcoming Studies